Watch live: Biden speaks about his negative Covid test and the broader pandemic effort

(Biden’s remarks are scheduled to begin at 11:30AM ET. Please refresh the page if the video above isn’t playing by then.)

President Joe Biden will deliver remarks in the White House Rose Garden after testing negative for Covid-19 and ending the strict isolation measures he had been following since contracting the coronavirus last week.

Biden’s symptoms “have been steadily improving, and are almost completely resolved,” wrote White House physician Dr. Kevin O’Connor in a letter released by the White House on Wednesday.

Biden, 79, will also discuss where the U.S. stands in its two-year battle against the virus.

On Wednesday morning the president tweeted a photo of his negative test along with the message, “Back to the Oval. Thanks to Doc for the good care, and to all of you for your support.”

Source

Health

Pfizer tops estimates, raises profit guidance even as sales fall

November 4, 2025

Smith Collection | Archive Photos | Getty Images Pfizer on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year profit guidance, as cost cuts helped to outweigh declining sales for the period. The pharmaceutical giant now expects its full-year adjusted profit to come in between $3 and $3.15 per share, up […]

Health

Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech

November 3, 2025

A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., Sept. 30, 2025. Mike Blake | Reuters Pfizer on Monday said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker’s attempt to outbid Pfizer to acquire the obesity biotech is […]

Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

October 30, 2025

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]